Engineering circular RNA for enhanced protein production.

Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA, Chang HY. · 2023

Read Engineering circular RNA for enhanced protein production. by Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA, Chang HY. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9931579.txt.

Introduction

Chen and co-authors engineer circular RNA to raise protein production. Circular RNAs are stable RNA rings found in eukaryotic cells. Some can encode proteins, which makes them a candidate platform for gene expression. The team built a fast system to assemble and test design features.

They tuned five elements that affect protein output. These were vector shape, both untranslated regions, ribosome entry sites, and aptamers. Together the changes raised yields by several hundred-fold. Output beat messenger RNA in lab tests and lasted longer in living tissue. The gains held across several test genes. The work gives designers a recipe for stronger circular RNA products. Such products could serve gene therapy and drug delivery.

Catalog record

CREATORChen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A, Abe BT, Chen CK, Wender PA, Chang HY.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC9931579

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Engineering circular RNA for enhanced protein production By Robert Chen, Sean K Wang, Julia A Belk, Laura Amaya, Zhijian Li, Angel Cardenas, Brian T Abe, Chun-Kan Chen, Paul A Wender, Howard Y Chang Published in: Nature Biotechnology DOI: 10.1038/s41587-022-01393-0 ABSTRACT Abstract Circular RNAs (circRNAs) are stable and prevalent RNAs in eukaryotic cells that arise from back-splicing. Synthetic circRNAs and some endogenous circRNAs can encode proteins, raising the promise of circRNA as a platform for gene expression. In this study, we developed a systematic approach for rapid assembly and testing of features that affect protein production from synthetic circRNAs. To maximize circRNA translation, we optimized five elements: vector topology, 5′ and 3′ untranslated regions, internal ribosome entry sites and synthetic aptamers recruiting translation initiation machinery. Together, these design principles improve circRNA protein yields by several hundred-fold, provide increased translation over messenger RNA in vitro, provide more durable translation in vivo and are generalizable across multiple transgenes. Subject terms: RNA splicing, Gene therapy, Gene delivery, Nucleic-acid therapeutics MAIN Ribonucleic acid (RNA) therapeutics—spanning messenger RNAs (mRNAs), small interfering RNAs (siRNAs) and micro RNAs (miRNAs)—have expanded into a novel pillar of modern medicine, joining small molecules, biologics and cell therapeutics. Recently, mRNA vaccines have drawn attention for addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic1,2. The rapid pace by which mRNAs can be designed, synthesized and tested has unlocked new ways to respond to urgent and evolving medical crises. In the backdrop of the worldwide success of mRNA medicines, circularization of coding RNAs into circRNAs has garnered considerable interest as an approach to extend the duration of protein translation. Originally investigated in the context of naturally occurring back-splicing, circRNAs are single-stranded RNA molecules covalently joined head to tail3. Considerable advancements have been made in synthesizing and circularizing long transcripts into circRNAs4,5. However, the fundamental mechanisms of translation initiation for circRNAs and mRNAs differ because circRNAs lack a 7-methylguanylate (m7G) cap. During mRNA translation, the m7G cap recruits eukaryotic initiation factor 4E (eIF4E), which, in synergy with eIF4A and eIF4G, scaffolds the recruitment of other initiation factors and the ribosome6. In contrast, because circRNAs are covalently linked head to tail and lack a 5′ terminus, they must rely on cap-independent mechanisms, such as internal ribosome entry sites (IRESs), to initiate translation. Although the ability of circRNAs containing IRESs to encode proteins has long been known7, the principles of circRNA translation have yet to be thoroughly dissected. Identification of these principles is necessary to build better circRNA therapeutics and potentially surpass the translation capabilities of mRNA. In this study, we created a modular high-throughput platform to make and test synthetic circRNAs. Using this platform, we systematically compare how circRNA expression is affected by factors including N6-methyladenosine (m6A) incorporation, vector topology, number of stop codons, 5′ and 3′ untranslated regions (UTRs), IRESs and synthetic aptamers. By optimizing and combining these elements for enhanced translation, we improve circRNA protein yields by several hundred-fold. RESULTS Development of a modular circRNA assembly platform Synthesis of circRNAs via intron-assisted splicing and RNaseR digestion has been previously described4, but rapid creation of different circRNA species was difficult. To enable higher-throughput testing of circRNAs, we created a modular cloning platform consisting of a set of backbones and parts in a clearly defined and adaptable format compatible with both Golden Gate8 and Gibson cloning9 (Fig. 1 and Supplementary Fig. 1a). After various iterations of backbones, we arrived at a version incorporating a T7 promoter for in vitro transcription (IVT), the T4 thymidylate synthase (td) intron for RNA circularization, homology sequences to assist with circularization and low-structure regions to facilitate RNaseR digestion of precursor linear RNA. To assess circRNA translation across many conditions, we adopted a NanoLuc10 luminescence assay because of its broad quantitative range (Supplementary Fig. 1b), compatibility with a multi-well plate format and ability to measure both secreted and intracellular forms of NanoLuc. Using this platform, we systematically determined how aspects of circRNA design affect circRNA translation. [Figure: A modular cloning platform for circRNA enables rapid design–build–test cycles.Schematic describing the modular cloning platform used to create template plasmids for circRNA synthesis. Parts 1–6 corresponding to the upstream intron and 5′ UTR, IRES, N-terminal (N′) tag, coding sequence (CDS), C-terminal (C′) tag and 3′ UTR and the downstream intron were individually cloned into part plasmids via Golden Gate reactions (Supplementary Fig. 1). Part plasmids and the circRNA backbone were then combined in a second Golden Gate reaction to create a circRNA plasmid. The circRNA backbone contains a CAG promoter enabling circRNA transcription after transient transfection in cellulo, a T7 promoter enabling IVT, homology sequences that assist with RNA circularization, low-structure regions that facilitate RNaseR processivity and a bacterially expressed GFP dropout sequence to negatively select for incorrect assemblies. If a CDS without N′ or C′ tags was used, parts 3–5 were replaced with a single part. PCR products from circRNA plasmids were subsequently used as templates for IVT to synthesize RNA. Lastly, RNaseR cleanup was performed to digest linear RNAs and isolate circRNA. DS, downstream.] m6A incorporation does not adversely affect circRNA translation We previously showed that circRNAs can trigger immune responses in vivo that can be avoided by modifying circRNAs with m6A4,11. However, the effect of m6A incorporation on circRNA translation is unknown. To address this, we used our cloning platform to synthesize unmodified circRNAs encoding either NanoLuc or the fluorescent protein mNeonGreen. In separate preparations, we synthesized the same circRNAs with 5% m6A incorporation. Compared to unmodified circRNAs, circRNAs containing 5% m6A showed equivalent translation after transfection or electroporation in vitro (Supplementary Fig. 2a,b). To gauge how m6A affected circRNA stability, we also performed an FBS degradation assay making use of the endogenous RNases in FBS (Supplementary Fig. 2c). CleanCap and 100% N1-methylpseudouridine (N1Ψ)-modified mRNA, the industry standard for mRNA-based therapies, was fully degraded by 1% FBS alongside unmodified circRNA. Conversely, circRNA containing 5% m6A was more resistant to nucleases and was not fully degraded until 2% FBS. These results indicate that 5% m6A incorporation does not adversely affect circRNA translation and may confer improved stability. Given their reduced immunogenicity11, we focused our subsequent optimization efforts on m6A-modified circRNAs. Moving forward, we incorporated 5% m6A in every circRNA preparation unless otherwise stated. Vector topology and spacer requirements for circRNA translation We first sought to uncover principles behind circRNA vector topology that are necessary for strong translation. We began by synthesizing circRNAs with a coxsackievirus B3 (CVB3) IRES (denoted iCVB3) downstream, or 3′, of the reporter NanoLuc gene, maintaining the reading frame through the residual scar formed by the self-splicing reaction of the T4 td intron (Fig. 2a). In this orientation, translation through the splicing scar is unavoidable. Hypothesizing that the highly structured scar sequence might obfuscate the translation start site, we generated circRNA variants with in-frame spacers of varying lengths between the translation start and the splicing scar. The peptides encoded by these spacers reflected consensus viral leader peptide sequences from the rhinovirus family. Testing the expression of these circRNAs suggested that increasing the spacer length was non-beneficial for translation and that the ribosome was unaffected by the td splicing scar’s secondary structure. [Figure: Optimization of RNA non-coding elements enable stronger circRNA translation.a, NanoLuc activity after transfection of HeLa cells

Read the complete text